RET and thyroid gland papillary carcinoma: The mesothelioma cell line EHMES-10 [17–19] containing a NCOA4-RET fusion, and human lung adenocarcinoma cell line LC-2/ad [20] and thyroid papillary carcinoma cell line TPC-1 [21] containing a CCDC6-RET fusion were used in this study.